Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Deepti H. Radia, MRCPI, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Philippe Rousselot, MDPhD, Katayoun Rezvani, MD PhD, Shahram Kordasti, MD PhD, Claire Harrison, DM, FRCP, FRCPath, Hugues de Lavallade, MD PhD

Blood (2020) 136 (Supplement 1): 51–53.

https://doi.org/10.1182/blood-2020-139501

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Henry Wood, MBBS, Katy Sanchez, BSc, MSc, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Austin Kulasekararaj, MD MRCP, FRCPath, Hugues de Lavallade, MD PhD, Deborah Yallop, MBBS, FRCP, FRCPath, PhD, Shireen Kassam, MBBS, FRCPath, PhD, Robin M. Ireland, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Alan Dunlop, BSc, MSc

Blood (2019) 134 (Supplement_1): 4566.

https://doi.org/10.1182/blood-2019-131711

Published: 2019

Journal Articles

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Aytug Kizilors, PhD, Elena Crisa, MD, Nicholas Lea, PhD, Steven Best, PhD, Mian Syed, PhD, Robin M. Ireland, FRCP, FRCPath, Maadh Aldouri, FRCPath, Christopher Pocock, Timothy Corbett, FRCP, FRCPath, Emily Elizabeth Bart-Smith, MRCP,BSc, Richard Gale, FRCPath, FRCP, Clare Wykes, FRCPath, FRCP, Simon Weston-Smith, FRCP, FRCPath, Donal McLornan, MDPhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Hugues de Lavallade, MD PhD

Blood (2015) 126 (23): 347.

https://doi.org/10.1182/blood.V126.23.347.347

Published: 2015

Journal Articles

Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Meng Wang, MD PhD, Wenjia Wang, PhD, Ayesha Abeywardane, MD, Malinthi Adikarama, MD, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Stephen Devereux, MD PhD FRCPath, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MD FRCP, FRCPath, Victoria T Potter, MD FRCPA, FRACP, Aleksandar Mijovic

Blood (2014) 124 (21): 2512.

https://doi.org/10.1182/blood.V124.21.2512.2512

Published: 2014

Journal Articles

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Francesco Grimaldi, MD, Linda D Barber, PhD, Pilar Perez-Abellan, MSc, Rosemary Grain, Victoria T Potter, MD FRCPA, FRACP, Austin Kulasekararaj, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Judith C Marsh, MD

Blood (2014) 124 (21): 1594.

https://doi.org/10.1182/blood.V124.21.1594.1594

Published: 2014

Journal Articles

Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity

Anita Sarma, MBChB, BSc, MRCP, Victoria T Potter, MD FRCPA, FRACP, Jennifer Clay, BM BS, FRACP, FRCPA, Donal McLornan, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Kavita Raj, Judith C. W. Marsh, Austin Kulasekararaj, Antonio Pagliuca, MD FRCP, FRCPath, Ghulam Mufti, MD DM, FRCP, FRCPath

Blood (2014) 124 (21): 1236.

https://doi.org/10.1182/blood.V124.21.1236.1236

Published: 2014

Journal Articles

Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome

Alesia Abigael Hunt, MBChB, Anjum Bashir Khan, MBChB, MRCP, Victoria T Potter, MD FRCPA, FRACP, Donal McLornan, MD PhD FRCPath, Kavita Raj, MDPhD, Hugues de Lavallade, MD MSc, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Alexander E Smith, PhD, Judith C Marsh, MD, Austin Kulasekararaj, Ghulam J Mufti, FRCP, FRCPath

Blood (2014) 124 (21): 3269.

https://doi.org/10.1182/blood.V124.21.3269.3269

Published: 2014

Journal Articles

B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease

Blood (2013) 122 (21): 4478.

https://doi.org/10.1182/blood.V122.21.4478.4478

Published: 2013

Journal Articles

CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy

MD Muharrem Muftuoglu, Abdullah Alsuliman, PhD, Ahmad Khoder, MD, Yong-Oon Ahn, PhD, Enli Liu, MD, MS, Claude Chew, Amir Hamdi, MD, Takuya Sekine, Anushruti Sarvaria, Nichola Cooper, MD, Hugues de Lavallade, MD, David Marin, MD, Kate Stringaris, MD, MRCP, FRCPath, Michael R. Verneris, MD, Elizabeth J Shpall, MD, Katayoun Rezvani, MD, PhD

Blood (2013) 122 (21): 2024.

https://doi.org/10.1182/blood.V122.21.2024.2024

Published: 2013

Journal Articles

Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN

Anjum Bashir Khan, MBChB, MRCP, Donal McLornan, MD, PhD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Kavita Raj, MD, PhD, MRCP, FRCPath, Victoria T Potter, MBBS, FRCPA, FRACP, Hugues de Lavallade, MD, Majid A Kazmi, BmedBiol MB ChB MRCP (UK) MRCPath, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Sangeeta Atwal, MBBS MRCP FRCPath, Victor Noriega, MD, Claire N Harrison, DM FRCP FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 4532.

https://doi.org/10.1182/blood.V120.21.4532.4532

Published: 2012

Journal Articles

HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS

Victor Noriega, MD, Hugues de Lavallade, MD, Victoria T Potter, MBBS, FRCPA, FRACP, Pramila Krishnamurthy, Judith C. W. Marsh, Prof MD PhD, Stephen Devereux, FRCP, FRCPath, Ph.D., Robert E. Marcus, MBBS, FRCP, FRCPath, Kavita Raj, Donal McLornan, MD, PhD, Anjum Bashir Khan, MBChB, MRCP, Sangeeta Atwal, MBBS MRCP FRCPath, Robin M. Ireland, FRCP, FRCPath, Deborah Yallop, BSc, FRCPath, MB, BS, MRCP, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, FRCP, FRCPath, M.D.

Blood (2012) 120 (21): 4158.

https://doi.org/10.1182/blood.V120.21.4158.4158

Published: 2012

Journal Articles

Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation

Sangeeta Atwal, MBBS, MRCP, FRCPath, Anjum Bashir Khan, MBChB, MRCP, Victor Noriega, MD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Michelle Kenyon, BSc, RN, Hugues de Lavallade, MD, Donal McLornan, MD, PhD, Victoria T Potter, MBBS, FRCPA, FRACP, Kavita Raj, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 4216.

https://doi.org/10.1182/blood.V120.21.4216.4216

Published: 2012

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

Blood (2010) 116 (21): 677.

https://doi.org/10.1182/blood.V116.21.677.677

Published: 2010

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Hugues de Lavallade, MD, MsC, Melanie Hart, PhD, Ian H Gabriel, Dr, Peter Kelleher, MD, PhD, Abdullah Alsuliman, PhD, Ahmad Khoder, MD, Dragana Milojkovic, MD, Letizia Foroni, Marco Bua, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, David Marin, MD, Katayoun Rezvani, MD, PhD

Blood (2009) 114 (22): 2214.

https://doi.org/10.1182/blood.V114.22.2214.2214

Published: 2009

Journal Articles

Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Mohamad Mohty, MD, PhD, Xavier Cahu, Catherine Faucher, MD, Patrice Chevallier, MD, Norbert Vey, MD, Jean El-Cheikh, MD, Thierry Guillaume, MD, Sabine Furst, MD, Jacques Delaunay, MD, Hugues de Lavallade, MD, Philippe Moreau, MD, Jean-Albert Gastaut, MD, Jean-Luc Harousseau, MD, Didier Blaise, MD

Blood (2007) 110 (11): 2001.

https://doi.org/10.1182/blood.V110.11.2001.2001

Published: 2007

NARROW

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity

Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome

B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease

CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy

Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN

HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS

Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only